Claims
- 1. A compound of formula ##STR15## or a pharmaceutically acceptable salt thereof wherein R.sup.1 and R.sup.2 are each independently hydrogen, a straight or branched alkyl of from one to eighteen carbon atoms, unsubstituted or substituted benzyl wherein the substituent is alkyl of from one to three carbon atoms, alkoxy of from one to four carbon atoms, halogen, aminoalkyl of from one to twelve carbon atoms which is unsubstituted, mono- or disubstituted on the nitrogen by benzyl or alkyl of from one to four carbon atoms alkoxycarbonylalkyl of from one to six carbon atoms or CH.sub.2 --CO--NR.sup.11 R.sup.12 wherein R.sup.11 and R.sup.12 are each independently hydrogen, alkyl of from one to six carbon atoms, benzyl, haloalkyl of from one to six carbon atoms, hydroxy alkyl of from one to six carbon atoms wherein R.sup.11 or R.sup.12 can each be unsubstituted or substituted by halogen, alkoxy alkyl, by one to three hydroxy groups, or R.sup.11 and R.sup.12 are each independently acyl of from one to four carbon atoms or glycoside;
- R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, and R.sup.10 are each independently hydrogen, halogen, alkyl of from one to four carbon atoms, alkoxy of from one to four carbon atoms, acyloxy of from one to four carbon atoms, nitro, amino which is unsubstituted or mono- or disubstituted by benzyl, alkyl of from one to four carbon atoms, benzyloxy, hydroxy, aminoalkoxy of from one to twelve carbon atoms and which nitrogen can be unsubstituted or mono- or disubstituted by benzyl or by alkyl of from one to four carbon atoms or the substituents form a ring containing from three to six carbon atoms or the alkyl is unsubstituted or substituted by alkyl of from one to four carbon atoms, hydroxy, alkoxy of from one to four carbon atoms, trifluoromethyl or two neighboring substituents form methylene,
- with the proviso that not all of R.sup.1 to R.sup.10 are hydrogen and R.sup.10 can also be cyanoalkyl or when R.sup.4 or R.sup.4 and R.sup.9 are hydroxy, the others of R.sup.1 to R.sup.10 are not hydrogen.
- 2. A compound according to claim 1 wherein R.sup.1 and R.sup.2 are each independently hydrogen, straight or branched alkyl of from one to four carbon atoms, aminoalkyl of from one to four carbon atoms which alkyl is unsubstituted or substituted by alkoxy of from one to four carbon atoms or by hydroxy and which nitrogen is unsubstituted, mono- or disubstituted by alkyl of from one to four carbon atoms;
- R.sup.3, R.sup.6, R.sup.7, and R.sup.10 are each hydrogen and R.sup.4, R.sup.5, R.sup.8, and R.sup.9 are each independently hydrogen, halogen, alkyl of from one to four carbon atoms, alkoxy of from one to four carbon atoms, benzyloxy, hydroxy, aminoalkoxy of from one to four carbon atoms, the alkyl portion of which is unsubstituted or substituted by alkoxy of from one to four carbon atoms and the nitrogen portion of which is unsubstituted, mono- or disubstituted by alkyl of from one to four carbon atoms or two substituents of R.sup.4, R.sup.5, R.sup.8, and R.sup.9 form a ring containing from three to six carbon atoms, wherein the alkyl chain is unsubstituted or substituted by an alkyl of from one to four carbon atoms or two substituents from R.sup.4, R.sup.5, R.sup.8, and R.sup.9 together form methylenedioxy.
- 3. A compound according to claim 1 wherein R.sup.1 and R.sup.2 are each independently hydrogen, straight or branched alkyl of from one to four carbon atoms, aminoalkyl of from one to four carbon atoms, the alkyl portion of which can be unsubstituted or substituted by alkoxy of from one to four carbon atoms and the nitrogen of which can be unsubstituted, mono- or disubstituted by alkyl of from one to four carbon atoms;
- R.sup.3, R.sup.6, R.sup.7, and R.sup.10 are each hydrogen;
- R.sup.4, R.sup.5, R.sup.8, and R.sup.9 are each independently hydrogen, alkyl of from one to four carbon atoms, alkoxy of from one to four carbon atoms, halogen, amino, nitro, dimethylamino, trifluoromethyl, benzyloxy, hydroxy, aminoalkoxy of from one to four carbon atoms, which alkyl portion is unsubstituted or substituted by alkoxy of from one to four carbon atoms and which nitrogen portion is unsubstituted or mono- or disubstituted by alkyl of from one to four carbon atoms or two adjacent substituents of R.sup.4, R.sup.5, R.sup.8, and R.sup.9 are together methylenedioxy.
- 4. A compound named 2-(1H-indol-3-yl)-3-(1-methyl-1H-indol-3-yl)-maleinimide.
- 5. A compound named 2-(1H-indol-3-yl-3-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]maleinimide.
- 6. A compound according to claim 1 named 2-(5-hydroxy-1H-indol-3-yl)-3-(1H-indol-3-yl)-maleinimide.
- 7. A compound according to claim 1 named 2-(5-benzyloxy-1H-indol-3-yl)-3-(1H-indol-3-yl)-maleinimide.
- 8. A compound according to claim 1 named 2,3-bis-(5-methoxy-1H-indol-3-yl)maleinimide.
- 9. A compound according to claim 1 named 2-(1H-indol-3-yl)-3-(5,6-methylenedioxy-1H-indol-3-yl)-maleinimide.
- 10. A compound according to claim 1 named 2-(1H-indol-3-yl)-3-(5,6-dimethoxy-1H-indol-3-yl)-maleinimide.
- 11. A compound according to claim 1 named 2,3-bis-(5,6-methylenedioxy-1H-indol-3-yl)-maleinimide.
- 12. A compound according to claim 1 named 2,3-bis(1-methyl-1H-indol-3-yl)-maleinimide.
- 13. A compound according to claim 1 selected from the group consisting of:
- 2-[1-(3-diethylaminopropyl)-6-methoxy-1H-indol-3-yl]-3-(5-methoxy-1H-indol-3-yl)-maleinimide,
- 2-[1-(3-diethylaminopropyl)-5-methoxy-1H-indol-3-yl]-3-(5,6-dimethoxy-1-methyl-1H-indol-3-yl)-maleinimide,
- 2-[1-(3-diethylaminopropyl)-5-methoxy-1H-indol-3-yl]-3-(6-methoxy-1H-indol-3-yl)-maleinimide, and
- 2-[1-(3-diethylaminopropyl)-6-methoxy-1H-indol-3-yl]-3-(5-methoxy-1H-indol-3-yl)-maleinimide.
- 14. A compound according to claim 1 selected from the group consisting of:
- 2-(1H-indol-3-yl)-3-(5-methoxy-1H-indol-3-yl)maleinimide,
- 2,3-bis-(5-fluoro-1H-indol-3-yl)-maleinimide,
- 2,3-bis-(5-benzyloxy-1H-indol-3-yl)maleinimide,
- 2,3-bis-(5-chloro-1H-indol-3-yl)maleinimide,
- 2,3-bis-(5-methyl-1H-indol-3-yl)maleinimide, and,
- 2,3-bis-(5-bromo-1H-indol-3-yl)maleinimide.
- 15. A compound according to claim 1 named 2-(5-bromo-1H-indol-3-yl)-3-(1H-indol-3-yl)-maleinamide.
- 16. A compound according to claim 1 named 2-(5-fluoro-1H-indol-3-yl)-3-(1H-indol-3-yl)-maleinimide.
- 17. A compound according to claim 1 named 2-[1-(3-diethylaminopropyl)-5-fluoro-1H-indol-3-yl]-3-(1H-indol-3-yl)maleinimide.
- 18. A compound according to claim 1 named (.+-.)-2-[1-(2,3-dihydroxypropyl)-5-methoxy-1H-indol-3-yl]-3-(1H-indol-3-yl)maleinimide.
- 19. A compound according to claim 1 named (.+-.)-2-[1-(3-ethoxy-2-hydroxypropyl)-5-methoxy-1H-indol-3-yl]-3-(1H-indol-3-yl)maleinimide.
- 20. A compound according to claim 1 named 2-[1-(2-cyanoethyl)-5-methoxy-1H-indol-3-yl]-3-(1-methyl-1H-indol-3-yl)maleinimide.
- 21. A compound according to claim 1 named 2-[1-(2-cyanoethyl)-1H-indol-3-yl]-3-(1-methyl-1H-indol-3-yl)maleinimide.
- 22. A compound according to claim 1 named 2-[1-(2-cyanoethyl)-1H-indol-3-yl]-3-(5-methoxy-1-methyl-1H-indol-3-yl)maleinimide.
- 23. A compound according to claim 1 named 2-(1H-indol-3-yl)-3-[1-(3-diisopropylaminopropyl)-1H-indol-3-yl]maleinimide.
- 24. A pharmaceutical composition for the treatment of heart and blood vessel diseases comprising an effective amount of a compound according to claim 1, including those compounds wherein R.sup.1 to R.sup.10 are hydrogen and those wherein R.sup.4 or R.sup.4 and R.sup.9 are hydroxyl and the remaining substituents of R.sup.1 to R.sup.10 are hydrogen, together with a pharmaceutically acceptable carrier.
- 25. A method of treating heart and blood vessel diseases in mammals which comprises administering to said mammal a pharmaceutical composition according to claim 24 in unit dosage form.
- 26. A compound according to claim 1 wherein R.sup.1 and R.sup.2 are each independently hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, benzyl, acetyl, methoxycarbonylmethyl, 2-methoxyethyl, 2-aminoethyl, 3-aminopropyl, 1-amino-2-propyl, 2-dimethylaminoethyl, 3-dimethylamino-1-propyl, 3-dimethlylamino-2-propyl, 2-diethylaminoethyl, 2-(N-benzyl -N-methylamino)-ethyl, 3-(N-benzyl-N-methylamino)-propyl, 3-dimethylamino-2-hydroxy-1-propyl, glucosyl, rhamnosyl, ribosyl, deoxyribosyl, aminoglycosyl, 3-hydroxypropyl, 2-carboxyethyl, 2-dimethylaminoethylcarbonyl, dimethylaminomethylcarbonyl, 2-hydroxyethoxymethyl, (2-hydroxy -1-hydroxymethyl)-ethoxymethyl or (3-hydroxy-1-hydroxymethyl)-propoxymethyl radicals and R.sup.5 and R.sup.8 are each independently hydrogen, chlorine, bromine, fluorine, trifluoromethyl, methyl, ethyl, hydroxyl, benzyloxy, methoxy, amino, dimethylamino, 2-aminoethoxy, 3-aminopropoxy, 1-amino-2-propoxy, 2-dimethylaminoethoxy, 3-dimethylamino-1-propoxy, 3-dimethylamino-2-propoxy, 2-diethylaminoethoxy, 2-[N-benzyl-N-methylamino]-ethoxy, 3-[N-benzyl-N methylamino]-propoxy, 3-dimethylamino-2-hydroxy -1-propoxy, or R.sup.4 and R.sup.5 together and R.sup.8 and R.sup.9 together are each independently methylenedioxy.
- 27. A compound selected from the group consisting of:
- 2-(5-benzyloxy-1H-indol-3-yl)-3-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]maleinimide,
- 2-[5-benzyloxy-1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)maleinimide,
- 2-(5-methoxy-1H-indol-3-yl)-3-[5-methoxy-1-(3-dimethylaminopropyl)-1H-indol-3-yl]maleinimide,
- (.+-.)-2-(1H-indol-3-yl)-3-[1-(3-dimethylamino-2-methoxypropyl)-1H-indol-3-yl]maleinimide,
- 2-(1H-indol-3-yl)-3-[5-(3-dimethylaminopropyloxy)-1H-indol-3-yl]maleinimide.
- 2-(5-fluoro-1H-indol-3-yl)-3-[5-fluoro-1-(3-dimethylaminopropyl)-1H-indol-3-yl]maleinimide,
- 2-(5-benzyloxy-1H-indol-3-yl)-3-[5-benzyloxy -1-(3-dimethylaminopropyl-1H-indol-3-yl]maleinimide,
- 2-[5-benzyloxy-1-(3-dimethylaminopropyl)-1H-indol-indol-3-yl]-3-(1-methyl-1H-indol-3-yl)maleinimide,
- 2-(5-chloro-1H-indol-3-yl)-3-[5-chloro-1-(3-dimethylaminopropyl)-1H-indol-3-yl]maleinimide,
- 2-(5-methyl-1H-indol-3-yl)-3-[5-methyl-1-(3-dimethylaminopropyl)-1H-indol-3-yl]maleinimide,
- 2-(5-bromo-1H-indol-3-yl)-3-[5-bromo-1-(3-dimethylaminopropyl)-1H-indol-3-yl]maleinimide,
- 2-(1H-indol-3-yl)-3-[1-(2-dimethylaminoethyl)-1H-indol-3-yl]maleinimide,
- 2-[1-(3-diethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)maleinimide,
- 2-(5-methoxy-1-indol-3-yl)-3-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]maleinimide,
- 2-(1H-indol-3-yl)-3-[5-methoxy-1-(3-dimethylaminopropyl)-1H-indol-3-yl]maleinimide,
- 2-(5-fluoro-1H-indol-3-yl)-3-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]maleinimide,
- 2-[1-(3-diethylaminopropyl)-5-methoxy-1H-indol-3-yl[-3-(1H-indol-3-yl)maleinimide,
- 2-[1-(3-diethylaminopropyl)-1H-indol-3-yl)-3-(5-methoxy-1H-indol-3-yl)maleinimide,
- 2-[5-fluoro-1-(3-dimethylaminopropyl)-1H-indol-3-yl)maleinimide, and
- 2-(5-fluoro-1H-indol-3-yl)-3-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]maleinimide.
- 28. A compound selected from the group consisting of:
- (.+-.)-2-[1-(3-diethylamino-2-hydroxypropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)maleinimide,
- (+)-2-[1-(3-diethylamino-2-hydroxypropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)maleinimide,
- (-)-2-[1-(3-diethylamino-2-hydroxypropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)maleinimide,
- (.+-.)-2-[1-(2,3-dihydroxypropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)maleinimide,
- (+)-2-[1-(2,3-dihydroxypropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)maleinimide,
- (-)-2-[1-(2,3-dihydroxypropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)maleinimide,
- (.+-.)-2-[1-(3-ethoxy-2-hydroxypropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)maleinimide,
- (+)-2-[1-(3-ethoxy-2-hydroxypropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)maleinimide,
- (-)-2-[1-(3-ethoxy-2-hydroxypropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)maleinimide,
- (.+-.)-2-[1-(3-diethylamino-2-hydroxypropyl)-5-methoxy-1H-indol-3-yl]-3-(1H-indol-3-yl)maleinimide,
- (+)-2-[1-(3-diethylamino-2-hydroxypropyl)-5-methoxy-1H-indol-3-yl]-3-(1H-indol-3-yl)maleinimide,
- (-)-2-[1-(3-diethylamino-2-hydroxypropyl)-5-methoxy-1H-indol-3-yl]-3-(1H-indol-3-yl)maleinimide,
- (.+-.)-2-[1-(3-diethylamino-2-hydroxypropyl)-1H-indol-3-yl]-3-(5-methoxy-1H-indol-3-yl)maleinimide,
- (+)-2-[1-(3-diethylamino-2-hydroxypropyl)-1H-indol-3-yl]-3-(5-methoxy-1H-indol-3-yl)maleinimide, and
- (-)-2-[1-(3-diethylamino-2-hydroxypropyl)-1H-indol-3-yl]-3-(5-methoxy-1H-indol-3-yl)maleinimide.
Priority Claims (2)
Number |
Date |
Country |
Kind |
3914764 |
May 1989 |
DEX |
|
3942991 |
Dec 1989 |
DEX |
|
Parent Case Info
This application is a continuation of U.S. Ser. No. 07/715,064, filed Jun. 11, 1991, which is a continuation-in-part of U.S. Ser. No. 07/515,795, filed Apr. 27, 1990, both abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4912107 |
Kleinschroth et al. |
Mar 1990 |
|
Non-Patent Literature Citations (2)
Entry |
Tetrahedron Letters, 28(38):4441-4444 (1987), J. Bergman et al., "Coupling of Indoleacetic Acid Trianion . . .". |
Febs Lett., 259(1): 61-63 (1989), P. D. Davis et al., "Potent Selective Inhibitors of Protein Kinase-C". |
Continuations (1)
|
Number |
Date |
Country |
Parent |
715064 |
Jun 1991 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
515795 |
Apr 1990 |
|